Pioneering the path to tissue regeneration
Revolutionizing Osteoarthritis Treatment with Adenosine
Regenosine is developing a first-in-class, disease-modifying regenerative therapy for osteoarthritis (OA) and other indications with unmet clinical needs utilizing a proprietary liposomal adenosine intraarticular injection.
the problem: Osteoarthritis
THE SOLUTION
Proprietary and Patented Slow-Release Adenosine Formulation
Proprietary and Patented Slow-Release Adenosine Formulation
Proprietary and Patented Slow-Release Adenosine Formulation
Regenosine's breakthrough intra-articular injection delivers a proprietary, non-toxic formula of liposomal adenosine with a slow release of up to 15 days in joints. This innovative treatment has demonstrated remarkable efficacy in reducing joint pain, halting the progression of the disease, and promoting cartilage regeneration
Third-Party Validated
Proprietary and Patented Slow-Release Adenosine Formulation
Proprietary and Patented Slow-Release Adenosine Formulation
Independent third-party evaluation affirms the efficacy of Regenosine's proprietary therapy, revealing significant long-term pain relief, enhanced functional recovery, improved range of motion, and a marked reduction in both radiological and histological signs of osteoarthritis progression in models with clinical relevance.
Slowing Disease Progression
Proprietary and Patented Slow-Release Adenosine Formulation
Slowing Disease Progression
As the only disease-modifying therapy currently in development, Regenosine's technology offers the potential to change the course of OA rather than just treating the symptoms. This pioneering approach aims to fundamentally alter the underlying mechanisms of the disease, offering hope for true healing and improved quality of life for millions affected by osteoarthritis.